News

<p>Actavis bought the API division for an undisclosed price. The acquisition provides Actavis with the ability to develop and manufacture its own APIs, the single largest cost component

Royalmount Pharma is collaborating with the NCI under a clinical trial agreement for the evaluation of the drug RM1812 as a cancer chemopreventive agent against colorectal cancer. Chemoprevention

Merck said the settlement resolves all of the issues that were in dispute. Under the agreement, the final net cash cost to Merck covers federal tax, net interest

BrainStorm's adult stem cell technology has shown efficacy in animal models of Parkinson's disease in previous preclinical trials. In those studies, stem cells derived from human bone-marrow were

“I believe these results are very promising and may provide a much needed alternative to current topical treatments such as corticosteroids,” said Professor Arieh Ingber, the head of

Hylenex recombinant is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs. Under the terms of the agreements, Baxter will pay Halozyme an

In the trial patients with relapsed or refractory chronic lymphocytic leukemia (CLL) received fludarabine plus cyclophosphamide chemotherapy with or without Genasense. This trial achieved its primary endpoint, which

While terms of the agreement are not disclosed, the focus of the agreement will be on studying the use of Favrille's active immunotherapy, FavId, in conjunction with Berlex's

PS433540 is the only dual-acting angiotensin and endothelin receptor antagonist (DARA) compound in development and it possesses two clinically validated mechanisms of action in a single compound. The